Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec departure
confidence 95%
filed 2026-06-23
Item 8.01
William Go, M.D., Ph.D., Chief Medical Officer of Janux Therapeutics, departed on June 23, 2026, under a termination without "Cause" under the Company's Change in Control and Severance Benefit Plan. The disclosure centers on the departure of a named executive officer and the triggering of severance benefits, making this a clear executive departure event. The company's statement that the transition does not affect development strategy or clinical timelines is a standard mitigation statement but does not change the materiality of the CMO's departure.
View raw filing on EDGAR →
8-K
Exec departure
confidence 94%
filed 2026-06-23
Item 5.02
Ben M. Palmer, Director, President, and Chief Executive Officer of RPC, Inc., notified the Company on June 16, 2026 of his decision to retire effective on the earlier of a successor being named or December 31, 2026, ending a 30-year tenure with the company including 4 years as CEO.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-23
Item 5.02
Tom Siragusa, Chief Financial Officer and Principal Financial Officer, gave notice of his intention to resign effective August 16, 2026, to pursue another opportunity.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-22
Item 5.02
Mary A. Tidlund resigned as a director of Valhi Inc, effective June 30, 2026. The disclosure centers on a director's departure from the board, with no indication of a replacement appointment or compensatory arrangement. The resignation was voluntary and not due to disagreement, but director departures are material events affecting board composition and governance.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-06-22
Item 5.02
Kevin J. Wheeler is retiring as Executive Chairman effective July 1, 2026, after three decades with the company and serving as CEO and Chairman. While Stephen Shafer's appointment as Chairman is also disclosed, the principal action centers on Wheeler's departure from his executive role. The filing emphasizes Wheeler's long tenure and impact, and his retirement is the triggering event for the organizational change.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-22
Item 5.02
Matt Bilunas, Senior Executive Vice President and Chief Financial Officer, is departing Best Buy effective July 31, 2026, after 20 years with the company and 7 years as CFO. The filing centers on his departure as the principal disclosed action, with separation benefits mentioned as a secondary matter. The departure of a CFO is material to investors assessing the registrant's financial leadership and continuity.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-06-22
Item 5.02
Michael Buhle ceased serving as Chief Executive Officer on June 17, 2026. While the filing also discloses John Fraser's appointment as Interim CEO, the principal disclosed action centers on the CEO's departure. The departure is material as it affects the registrant's leadership and investor assessment of operational continuity, though the non-contentious nature and interim replacement arrangement somewhat mitigate the severity.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-22
Item 5.02
Mary A. Tidlund resigned as a director effective June 30, 2026, with no disagreement cited. This is a straightforward director departure disclosure under Item 5.02. Director changes are material to investors as they affect board composition and governance, and the filing explicitly addresses the departure as the principal event.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-22
Item 5.02
John W. Swann III, President of the Detection and Measurement Segment, informed the Company on June 18, 2026 of his decision to retire in January 2027. This is a clear executive departure—a named officer's announced retirement. The departure of a segment president is material to investors assessing management continuity and operational leadership.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-22
Item 5.02
Two directors, David Wodlinger and Henry Albers, resigned from the Board effective June 17, 2026. While the filing notes their resignations were not due to disagreement with management, the departure of two board members designated by a significant shareholder (Arlington Capital Partners) represents a material change in board composition and governance structure.
View raw filing on EDGAR →
6-K
Exec departure
confidence 75%
filed 2026-06-22
The filing discloses the resignation of Ms. Enriqueta Felip Font from her position as a member of the Board of Directors and the Sustainability, Communication and Reputation Committee, effective June 19, 2026. While the filing also announces the appointment of a replacement director (Ms. Ester Masllorens Llinàs) and committee member (Mr. Pascal Ravery), the principal disclosed action is the departure of an existing board member. Board-level departures are material to investors' assessment of governance and continuity.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-06-22
Item 5.02
Dr. Steve Kelsey, President of Research and Development, informed the Company of his intent to retire from employment effective January 4, 2027, with a transition to senior advisor role beginning July 1, 2026.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-06-22
Item 5.02
Dr. Ichiro Aoki, co-founder and President of indie Semiconductor, resigned from the Board and his President role effective June 29, 2026, transitioning to a limited technical advisor role. Thomas Schiller was concurrently appointed to the Board as part of the leadership transition.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-06-22
Item 5.02
Kendall Forbes, Executive Vice President of Sales & Operations since the company's founding in 2004, is retiring effective July 1, 2026, after 22 years of service.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-22
Item 5.02
The disclosure centers on the separation of Randall L. Baker, Chief Operating Officer, effective June 16, 2026. While the filing mentions severance benefits under the Executive Severance Plan, the principal disclosed action is the departure of a named executive officer from his role, making this an exec_departure event. The COO position is material to a reasonable investor's assessment of the company's leadership and operations.
View raw filing on EDGAR →
6-K
Exec departure
confidence 95%
filed 2026-06-22
The filing discloses that Karine Pinto-Flomenboim, the Company's Chief Financial Officer, has accepted a position at another company (Valens Semiconductor) and will depart her role on August 8, 2026, following Q2'26 results release. This is a departure of a named executive officer and material to investors assessing the registrant's financial leadership and continuity.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-22
Item 5.02
Ms. Inna Martin resigned from her positions as Director, Chief Operating Officer, and President of Revium Rx, effective immediately on June 16, 2026. The filing centers on her departure from multiple senior leadership roles, with the separation agreement detailing the terms of her exit, including extended stock option exercise periods and sale restrictions. This is a material executive departure affecting the company's leadership structure.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-06-22
Item 5.02
Gil Issachar departed his role as Chief Technology Officer (a named executive officer position) on June 18, 2026, and was reclassified as no longer a Section 16 officer or executive officer. Although he transitioned to a new role as Head of AI and Neuroscience, the material disclosure centers on his departure from the CTO position and loss of executive officer status, which is the salient event for investors assessing leadership changes.
View raw filing on EDGAR →
8-K
Exec departure
confidence 85%
filed 2026-06-22
Item 5.02
Panos Kozanian, Executive Vice President of Product Engineering, is departing Five9 effective June 29, 2026, with a transition period through at least September 4, 2026. Although the filing describes this as a "mutual agreement to begin a transition," the core disclosed action is the departure of a named executive officer from his role. The severance eligibility under the Key Employee Severance Plan further confirms this is a departure event rather than a routine reassignment.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-06-22
Item 5.02
Jeremy Kinch departed as Chief Operating Officer effective June 22, 2026, treated as a termination without cause and unrelated to financial or accounting issues; CEO Koti Vadlamudi assumed interim COO duties.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-06-22
Item 5.02
Mark A. Pytosh stepped down from his position as President and Chief Executive Officer of CVR Energy and CVR GP, and from both boards, effective June 18, 2026, pursuant to a Separation Agreement, with a separation payment of $3,000,000 and post-employment restrictions.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-22
Item 5.02
Andrew Wattula, Chief Operating Officer since 2021, resigned on June 18, 2026. The disclosure centers on his departure from a senior executive role, with his duties reassigned to existing officers while the company considers backfilling. This is a material executive departure requiring Item 5.02 disclosure.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-22
Allison W. Brady resigned from the Board of Directors effective immediately on June 17, 2026, and also resigned from her positions on the Audit Committee and Compensation Committee. This is a clear departure of a director from the company's governance structure. The filing explicitly states her resignation was not due to disagreement, but the departure itself is a material governance event affecting board composition.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-06-22
The filing's primary Item 5.02 disclosure centers on the resignation of James Hendrickson, President and Chief Operating Officer, effective immediately on June 15, 2026, due to disagreements with the Board regarding compensation practices and non-payment of earned wages. While the press release also announces discontinuation of AI operations and pursuit of strategic alternatives, the Item 5.02 structure and the explicit resignation statement make the executive departure the principal disclosed event, though the operational pivot is material context.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-22
Item 5.02
Marc Winterhoff, Chief Operating Officer of Lucid Group, Inc., departed the Company effective immediately following the elimination of the COO position.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-22
Item 5.02
Dr. Noah Berkowitz, the Company's chief medical officer, is departing effective July 3, 2026. While the disclosure includes severance terms (base salary continuation, health coverage, and RSU acceleration), the principal disclosed action is the departure of a named executive officer from his role. The filing centers on the departure event and the separation agreement executed in connection with it.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-22
Item 5.02
Jeffrey Horowitz, Chief Compliance Officer, gave notice of retirement effective June 19, 2026. The filing explicitly states his departure was not due to disagreement with the Company. This is a straightforward executive departure of a named officer in a compliance-critical role, material to investor assessment of the registrant's governance and risk management structure.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-06-18
Item 5.02
Dave Denton, Chief Financial Officer, is stepping down from his position effective August 15, 2026, to pursue a professional opportunity outside the pharmaceutical industry. While the filing also discloses the interim appointment of Cecile Guegan as Interim CFO, the principal disclosed action centers on Denton's departure—a material executive departure at the C-suite level. The CFO role is critical to investor assessment of financial stewardship and strategy execution.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-06-18
Item 5.02
John W. Rogers, Jr., a director since 2018, is retiring from the Board of Directors effective at the 2026 Annual Meeting and will not stand for re-election. Although he will transition to a strategic advisor role, his departure from the Board represents a material change in the company's governance structure.
View raw filing on EDGAR →
8-K
Exec departure
confidence 85%
filed 2026-06-18
Item 5.02
S. Dustin Crone, President and Chief Executive Officer of C&F Finance, informed the Boards of his intention to retire effective December 31, 2026, with his President role ending June 30, 2026. While the filing also discloses a transition agreement and compensatory arrangements, the principal disclosed action is the departure of a named executive officer from a senior leadership position. The material event centers on the CEO's planned retirement and transition, making exec_departure the most salient classification.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-06-18
Item 5.02
Two Co-CEOs (Steven Gagnon and John LaViolette) and Vice-President Sasha Shapiro resigned on June 17, 2026, materially affecting the registrant's senior leadership structure.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-18
Item 5.02
Dr. Michael Cuffe, Executive Vice President and Chief Clinical Officer, is stepping down effective August 31, 2026, with a transitional role through February 2027. This is a departure of a named executive officer from a senior leadership position. While severance benefits are mentioned, the principal disclosed action is the departure itself, making this an exec_departure event rather than exec_compensation.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-18
Item 5.02
Andrew C. Carington departed Hamilton Beach Brands as Senior Vice President, General Counsel and Secretary, effective immediately on June 18, 2026. The departure of a senior executive holding the General Counsel position—a key officer responsible for legal and governance matters—is material to investors' assessment of the company's leadership and operational continuity.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-06-18
Item 5.02
Caroline Tsai, Chief Legal & Corporate Affairs Officer and Corporate Secretary, is stepping down effective July 1, 2026. While the filing also discloses Chip Keller's appointment as Chief Legal Officer, the primary disclosed action centers on Ms. Tsai's departure after four years with the company. The filing emphasizes her role in major transactions (Worldpay divestiture and TSYS acquisition), making her departure material to investors.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-06-18
Item 5.02
Vishwas Setia's separation as Chief Financial Officer is the primary disclosed action, effective immediately following an HR violation review. While Jonathan Gillis's appointment as interim CFO is also disclosed, the filing centers on Setia's departure and the circumstances surrounding it (separation agreement, COBRA coverage). The CFO role is a named executive officer position material to investors' assessment of the company's financial leadership and governance.
View raw filing on EDGAR →
6-K
Exec departure
confidence 92%
filed 2026-06-18
Ms. Liu Liangping resigned from her position as Director of the Board effective immediately on June 18, 2026. Although she retains her COO role and other subsidiary positions, the departure from the Board constitutes a material executive departure. The stated reason—to devote herself to M&A projects—and the explicit statement that the resignation is not due to disagreement suggest an orderly transition, but Board-level departures are material to investors assessing governance and leadership continuity.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-18
Item 5.02
Katherine Rubenstein departed her role as Chief Operating Officer of Blackstone Secured Lending Fund on June 15, 2026, to pursue other opportunities. The disclosure explicitly states this was not due to any disagreement with the Fund's operations or policies. This is a straightforward executive departure of a named officer, material to investors assessing the Fund's management continuity and operational leadership.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-18
Item 5.02
Katherine Rubenstein departed her role as Chief Operating Officer of Blackstone Private Credit Fund on June 15, 2026. The disclosure explicitly states her departure was not due to disagreement with the Fund's operations or policies. This is a straightforward executive departure of a named officer, filed under Item 5.02, and is material as it involves a senior operational executive leaving the organization.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-06-18
Item 5.02
The filing discloses the resignation of three directors (Meghji, Fader-Rattner, Perkal) and three principal officers effective June 18, 2026: CEO Robert Rivas Collins, CFO Eric Greenhaus, and COO Matthew Perkal. While the filing also includes appointments of Chinh Chu as principal executive officer and Thomas Boychuk as CFO, the dominant narrative centers on the departures of key leadership. The simultaneous departure of the CEO, CFO, and COO, along with three board members, represents a material change in control and governance structure that would affect a reasonable investor's assessment of the company.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-18
Item 5.02
The disclosure centers on the departure of David Kronenfeld, the Company's general counsel, effective August 7, 2026, pursuant to a transition and separation agreement. While the filing details severance payments and accelerated vesting of restricted stock units, the principal disclosed action is the executive's departure from his role. The material nature is evident from the severance package value (cash, benefits, and equity acceleration totaling substantial consideration) and the executive's position as general counsel.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-18
Item 5.02
James Cabral ceased serving as Chief Operating Officer effective June 16, 2026, and is no longer employed by the Company. This is a clear departure of a named executive officer from a material position. The filing explicitly states the departure was not due to disagreement, but the event itself—loss of a COO—is material to investors assessing management continuity and operational leadership.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-18
Item 5.02
Todd P. Helms, Senior Vice President and Chief Human Resources Officer, is departing Mueller Water Products effective September 1, 2026. The disclosure centers on his departure and associated severance benefits under the Company's Executive Severance Plan, making this a clear executive departure event. The subsequent consulting arrangement is ancillary to the principal action of his departure.
View raw filing on EDGAR →
8-K
Exec departure
confidence 85%
filed 2026-06-18
Item 5.02
J. Wesley Sutherland's departure as Chief Accounting Officer effective June 16, 2026, is the principal disclosed action. While the filing also mentions Walter J. Phifer assuming the interim Principal Accounting Officer role, the core event centers on Sutherland's departure and planned retirement on September 30, 2026. The Chief Accounting Officer is a named executive officer responsible for financial reporting integrity, making this departure material to investors.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-06-18
Item 5.02
Craig Hurlbert resigned as Executive Chairman and Board member effective June 18, 2026, and Matthew Nordby resigned as Board member and Lead Independent Director effective the same date. While the filing also discloses new Board appointments and committee assignments, the principal disclosed action centers on the departure of two senior directors, particularly Hurlbert who held the Executive Chairman role. The departures are material as they represent significant changes in Board leadership and governance structure.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-18
Item 5.02
Cory Onell, Executive Vice President and Chief Omnichannel Sales and Asia Emerging Markets Officer, is stepping down from his role effective June 30, 2026. While the disclosure mentions severance payments and a prorated bonus, the principal disclosed action is the departure of a named executive officer from a significant leadership position. This is material as it affects the company's senior management structure and operational leadership.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-18
Item 5.02
Rich Hossfeld resigned from the Board and Audit Committee effective June 12, 2026. The principal disclosed action is a director's departure. While the filing also mentions Raffi Garabedian replacing him on the Audit Committee, the core event is Hossfeld's resignation. The company explicitly states the resignation was not due to disagreement, and board composition changes are material to investors assessing governance and oversight.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-17
Item 5.02
Daniel L. Poland, Executive Vice President and Chief Enterprise Transformation Officer, is stepping down from his current role effective August 3, 2026, with a transition period extending to January 10, 2027. This is a clear executive departure of a named officer at the C-suite level, making it material to investors assessing the company's leadership and operational continuity.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-06-17
Item 5.02
Richard Morrissy resigned from the Company's Board of Directors effective immediately on June 14, 2026, due to health concerns limiting his ability to serve. This is a clear director departure disclosure under Item 5.02, and board composition changes are material to investors assessing governance and continuity.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-06-17
Item 5.02
John E. Gallagher III, Senior Vice President and Chief Financial Officer, resigned effective July 14, 2026. Faiz Mohammed was appointed as Interim CFO to manage the transition.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-06-17
Item 5.02
Daniel J. Thoren, Executive Chairman and director, notified the Company on June 15, 2026 of his intention to step down from both positions effective immediately, with transition arrangements and continued compensation as a Strategic Advisor.
View raw filing on EDGAR →